WuXi Biologics announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking an important milestone as the company advances toward GMP release for production by the end of 2026. The microbial manufacturing site, broke ground last June in Wenjiang District of Chengdu, spans approximately 95,000 square meters and is designed for commercial drug substance (DS) and drug product (DP) manufacturing of microbial-derived biologics. Upon completion, the manufacturing site will be equipped with a 15,000 L fermenter, enabling up to 110 DS batches annually, with long-term expansion potential up to 60,000 L. It will also feature China's first dual-chamber lyophilization production line, jointly established with VISEN Pharmaceuticals, along with a vial-filling line that offers commercial DP manufacturing capacity of more than 10 million vials per year, further enhancing its commercial manufacturing capabilities for complex formulations.
In addition, the manufacturing site incorporates integrated automation and digital systems across upstream and downstream operations to support reliable GMP manufacturing, strengthening compliance, operational efficiency, and data integrity. ESG concepts are also embedded into the site's design through green building practices such as sponge city design and the adoption of photovoltaic (PV) modules, enhancing overall resource and energy efficiency.
